Hodgkin lymphoma, a distinctive cancer affecting the lymphatic system, poses challenges in treatment due to its unique characteristics and the limitations of traditional therapies. This essay delves into the potential of immunotherapy to transform the landscape of treatment for Hodgkin lymphoma. Furthermore, the essay analyses case studies to illustrate the efficacy of these approaches. It presents an overview of the underlying principles, as well as specific immunotherapeutic approaches, such as checkpoint inhibitors, monoclonal antibodies, and CAR-T cell therapy, and their mechanisms. Immunotherapy offers a targeted and personalized alternative to conventional chemotherapy and radiation, presenting promising results in clinical trials. Clinicians manage subtleties in immune-related toxicity and response assessment as the field develops. The goal of immunotherapy research in the initial phases of treatment is to increase cure rates while lowering long-term dangers. Ongoing research and advancements, including checkpoint blockade studies, offer hope for refining treatment approaches and optimizing outcomes in Hodgkin lymphoma. This essay emphasizes the significance of immunotherapy in providing effective and less toxic alternatives, heralding a new era in Hodgkin lymphoma treatment.